Company Profile
Arrowhead Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- ARWR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
85.83 USD (-1.24%)
Close
Last updated: August 6, 2026
9.98B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ARWR closed down 1.24% at $85.83. No new same-company headline was identified in the current news window.
Company overview
RNA Interference Platform
Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease-causing genes. Its delivery technologies support programs targeting the liver and other tissues.
REDEMPLO
REDEMPLO, or plozasiran, is an RNAi therapy targeting APOC3. It is approved in the United States to reduce triglycerides in adults with familial chylomicronemia syndrome and is under review in additional regions.
Dual-Target Cardiometabolic RNAi
ARO-DIMER-PA is a dual-functional RNAi candidate designed to silence both PCSK9 and APOC3 in a single molecule for atherosclerotic cardiovascular disease associated with mixed hyperlipidemia.
Obesity Programs
ARO-INHBE and ARO-ALK7 are RNAi candidates targeting adipose biology. Early clinical development is assessing effects on weight loss and body composition in people with obesity.
Liver-Disease and Partnered Pipeline
ARO-PNPLA3 targets a genetically defined form of liver disease and is partnered with Madrigal. Arrowhead also advances programs across pulmonary, neuromuscular and other tissues using its TRiM platform.
Future catalysts
European Commission decision on marketing authorization for REDEMPLO in the second quarter of 2026.
Recent news
- 01
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
Source: Arrowhead Pharmaceuticals
- 02
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
Source: Arrowhead Pharmaceuticals
- 03
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Source: Arrowhead Pharmaceuticals
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Arrowhead Pharmaceuticals (ARWR)?
Arrowhead Pharmaceuticals (ARWR) most recently closed at 85.83 USD, a -1.24% move versus the previous session.
What is the market cap of Arrowhead Pharmaceuticals (ARWR)?
Arrowhead Pharmaceuticals currently has a market capitalization of 9.98B USD on BioPharmSignal.
What does Arrowhead Pharmaceuticals do?
RNA Interference Platform Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease-causing genes. Its delivery technologies support programs targeting the liver and other tissues. REDEMPLO REDEMPLO, or plozasiran, is an RNAi therapy targeting APOC3. It is approved in the United States to reduce triglycerides in adults with familial...
On which exchange is ARWR stock listed?
Arrowhead Pharmaceuticals (ARWR) is associated with NASDAQ, United States, Biopharma.
What is ARO-DIMER-PA?
Dual-Target Cardiometabolic RNAi ARO-DIMER-PA is a dual-functional RNAi candidate designed to silence both PCSK9 and APOC3 in a single molecule for atherosclerotic cardiovascular disease associated with mixed hyperlipidemia.
Which conditions is Arrowhead Pharmaceuticals targeting with ARO-DIMER-PA?
Arrowhead Pharmaceuticals is associated with cardiovascular disease, metabolic disease, obesity based on its company overview and current catalyst commentary.
How does Arrowhead Pharmaceuticals describe recent progress with ARO-DIMER-PA?
European Commission decision on marketing authorization for REDEMPLO in the second quarter of 2026.
What is ARO-INHBE?
Obesity Programs ARO-INHBE and ARO-ALK7 are RNAi candidates targeting adipose biology.